Addressing Disease Burden in Asthma

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

Moderate-to-Severe Asthma Management

Systemic Lupus Erythematosus

Clinical Trials in IBD.

New Psoriasis Treatments

Unraveling Clinical Developments in NASH

Improving Survival in Glioblastoma Multiforme

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Progression After Cancer Immunotherapy in Advanced NSCLC

Clinical Review.

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Atopic Dermatitis Treatment Landscape

Updates in Management of Atopic Dermatitis From Real Patient Cases

Atopic Dermatitis Treatment Landscape

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Asthma and Atopic Comorbidities

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

New Recommendations on How to Stage Hidradenitis Suppurativa

New Data on Emerging Treatments for Psoriasis

When Is Biologic Therapy Appropriate for HS?

Personalizing Management in the Care of Patients With Advanced Sarcoma

Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Developments in the Wet AMD Treatment Landscape

Parkinson Disease Psychosis

Getting to Grips With the Science of CGRP and Migraine

Immune Checkpoint Inhibitors in Lung Cancer

Advances in Severe Asthma Management

Guide to Atopic Dermatitis

Current Issues and Emerging Advances in the Management of PKU

Challenges in Severe Asthma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

HAE Prophylaxis.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Peanut Allergy Immunotherapy

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pathophysiologic Targets of Allergic Asthma

Immune Checkpoint Inhibitors in Lung Cancer

Foundations of Asthma.

Presentation transcript:

Addressing Disease Burden in Asthma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Disease Burden of Asthma

Looking Forward Improving Patient QoL

Severe Asthma vs Uncontrolled Asthma Episodic Disease

When to Refer to a Specialist

Atopic Conditions Allergic March

The 'March': Allergic Relationships Children

Allergic Relationships Adults

Defining T2-High Asthma

Use of Biomarkers for Assessment of Asthma

Clinical Use of Biomarkers

Pathways for Targeted Therapies

Omalizumab

IL-5 Targeted Agents

Pathways for IL-5 Targeted Agents

Emerging Treatment Dupilumab

Emerging Treatment Dupilumab QUEST Study

Emerging Treatment Dupilumab QUEST Study Results

Emerging Treatment Tezepelumab

Emerging Treatment Fevipiprant

Approaches to Treatment

Assessment and Management

Concluding Remarks

Abbreviations

Abbreviations (cont)